8-K
filed May 18, 2023, 7:59 PM ET
ticker SNDX
CIK 0001395937
other material
confidence high
sentiment neutral
materiality 0.50
Syndax shareholders approve increase in authorized shares from 110M to 210M
Syndax Pharmaceuticals Inc
- Amendment to certificate of incorporation increases authorized shares: 200M common stock + 10M preferred stock.
- All four proposals passed at May 17, 2023 annual meeting; directors elected with majority support.
- Advisory vote on executive compensation passed with 58.1M for vs 0.8M against; auditor ratified.
- Increase provides flexibility for potential future equity financings or corporate actions.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Syndax Pharmaceuticals Inc: Increased authorized shares from 110,000,000 to 210,000,000, consisting of 200,000,000 common shares and 10,000,000 preferred shares (effective 2023-05-17).
- Change
- charter amendment
- Effective
- 2023-05-17
Exact text from the filing
On May 17, 2023, following receipt of the affirmative vote from the holders of a majority of the outstanding shares of common stock of Syndax Pharmaceuticals, Inc. (the “ Company ”) at the Annual Meeting (as defined below), the Company filed a certificate of amendment to the Company’s amended and restated certificate of incorporation (the “ Certificate Amendment ”) with the Secretary of State of the State of Delaware to increase the authorized number of total shares of all classes of stock that the Company has authority to issue from 110,000,000 shares to 210,000,000 shares, consisting of two classes: (1) 200,000,000 shares of common stock, $0.0001 par value per share, and (2) 10,000,000 shares of preferred stock, $0.001 par value per share. The Certificate Amendment became effective immediately upon filing.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Syndax Pharmaceuticals Inc shareholders approved Approval of amendment to the Company’s amended and restated certificate of incorporation to increase the number of authorized shares of common stock at the 2023-05-17 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-05-17
Exact text from the filing
Proposal 4 : Approval of amendment to the Company’s amended and restated certificate of incorporation to increase the number of authorized shares of common stock: For Against Abstain Broker Non-Votes 62,460,712 675,568 6,907 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Syndax Pharmaceuticals Inc shareholders approved Advisory vote on executive compensation at the 2023-05-17 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-17
Exact text from the filing
Proposal 2 : Advisory vote on executive compensation: For Against Abstain Broker Non-Votes 58,132,013 787,719 8,890 4,214,565
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Syndax Pharmaceuticals Inc shareholders approved Election of directors at the 2023-05-17 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-17
Exact text from the filing
Proposal 1 : Election of directors: Nominee For Withheld Broker Non-Votes Pierre Legault 35,300,479 23,628,143 4,214,565 Michael A. Metzger 57,418,793 1,509,829 4,214,565
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Syndax Pharmaceuticals Inc shareholders approved Ratification of selection of independent registered public accounting firm at the 2023-05-17 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-17
Exact text from the filing
Proposal 3 : Ratification of selection of independent registered public accounting firm: For Against Abstain Broker Non-Votes 63,037,788 103,402 1,997 —
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.